[Clinical application of anagrelide as a selective inhibitor of megakaryocyte system].
Anagrelid is, in our country, comparatively a new compound selectively affecting the megakaryocyte line in bone marrow leading to its reversal inhibition, simultaneously showing some exceptional, interesting pharmacological features. Essential trombocythemia, being a sole indication for the drug administration, is one of the chronic myeloproliferative disorders which exposes individuals to significantly increased risk for thrombohaemorrhagic complications. Regarding the latest literature data, the most present therapeutic modalities in this disease were presented focusing the interest on anagrelid being, in majority of cases, the drug of choice in uncontrolled megakaryocyte proliferation. The drug therapeutic value and characteristics were presented on the background of another compounds regarded as standard therapeutic options for essential thrombocythemia.
Najda
Jacek
J
Katedry i Kliniki Hematologii i Transplantacji Szpiku Slaskiej Akademii Medycznej w Katowicach.
Stella-Hołowiecka
Beata
B
D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011799:Quinazolines / Q000494:pharmacology* / Q000627:therapeutic use; D013922:Thrombocytosis / Q000188:drug therapy; D034061:Thrombopoiesis / Q000187:drug effects*
D005343:Fibrinolytic Agents; D011799:Quinazolines; C021139:anagrelide